Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Status:
Withdrawn

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Galecto Biotech AB

Collaborator:

Covance